Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8251 to 8265 of 8987 results

  1. Galcanezumab for preventing cluster headache [ID1212]

    Discontinued Reference number: GID-TA10425

  2. Erythrocyte encapsulated asparaginase for treating acute lymphoblastic leukaemia [ID864]

    Discontinued Reference number: GID-TA10047

  3. Durvalumab for untreated metastatic non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1331]

    Discontinued Reference number: GID-TA10318

  4. Masitinib for treating amyotrophic lateral sclerosis [ID967]

    Discontinued Reference number: GID-TA10157

  5. Idelalisib with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia [ID839]

    Discontinued Reference number: GID-TA10109

  6. Housing: planning to improve health and wellbeing

    Discontinued Reference number: GID-NG10053

  7. Iclepertin for treating cognitive impairment associated with schizophrenia [ID6483]

    Discontinued Reference number: GID-TA11647

  8. Neuro-Cells stem-cell treatment for traumatic spinal cord injury [ID6588]

    In development Reference number: GID-TA11629 Expected publication date: TBC

  9. GID-MT557 Novii Wireless Patch System for maternal and fetal monitoring (MT509)

    Discontinued Reference number: GID-MT557

  10. High tibial osteotomy with adjustable magnetic nail insertion for symptomatic medial knee osteoarthritis

    Discontinued Reference number: GID-IPG10142

  11. Intravenous zanamivir for treating influenza in hospital [ID1196]

    Discontinued Reference number: GID-TA10298

  12. Bimekizumab for treating active non-radiographic axial spondyloarthritis [ID4010]

    Discontinued Reference number: GID-TA11151

  13. Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]

    Discontinued Reference number: GID-TA10151

  14. Workplace health for employees with disabilities and long-term conditions

    Discontinued Reference number: GID-PHG58

  15. Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]

    Discontinued Reference number: GID-TA10566